Effects of resveratrol on insulin sensitivity, brown adipose tissue and metabolic profile in first-degree relatives of type 2 diabetic patients

Effects of resveratrol on insulin sensitivity, brown adipose tissue and metabolic profile in first-degree relatives of type 2 diabetic patients - Resveratrol and pre-diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON45176

Enrollment

Registered

2014-03-19

Start date

2014-05-26

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obesitas and sugar disease

Interventions

Subjects will be asked to take two pills of resveratrol 75 mg, or placebo, twice daily (lunch and diner), for 30 days, which will be randomized. Resveratrol (resvidaTM) is a food supplement and is r

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Male sex * Age: 40-70 years * BMI 27-35 kg/m2 * Has first-degree relative(s) diagnosed with type 2 diabetes * Sedentary: o Not more than 2 hours of sports a week o No active job that requires strenuous physical activity * Stable dietary habits: no weight gain or loss > 5kg in the last three months * Insulin resistant: glucose clearance rate

Exclusion criteria

Exclusion criteria: * Use of anticoagulants * Uncontrolled hypertension * Haemoglobin 6.5% * Diagnosed with type 2 diabetes * Medication use known to interfere with glucose homeostasis/metabolism * Current alcohol consumption > 20 grams/day * Subjects who don*t want to be informed about unexpected medical findings during the screening /study, or do not wish that their physician is informed, cannot participate in the study. * Subjects who intend to donate blood during the intervention or subjects who have donated blood less than three months before the start of the intervention. * Participation in another biomedical study within 1 month before the screening visit * Any contra-indication to MRI scanning: o Central nervous system aneurysm clip o Implanted neural stimulator o Implanted cardiac pacemaker of defibrillator o Cochlear implant o Insulin pump o Metal containing corpora aliena in the eye or brains For the 18F-FDG PET-CT scan: o Participation in earlier research or medical examinations that included PET/CT scanning

Design outcomes

Primary

Measure	Time frame
The main study endpoints are the differences in whole body- and muscle insulin sensitivity, and mitochondrial fat oxidative capacity after 30 days of resveratrol supplementation compared to the placebo trial.	—

Secondary

Measure	Time frame
Secondary outcome measures are the changes in liver and muscle fat storage after 30 days of resveratrol or placebo supplementation. Also, in 9 subjects we want to determine brown adipose tissue activity on day 33.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)